IFN-beta decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome

Neurology. 2001 Nov 13;57(9):1704-6. doi: 10.1212/wnl.57.9.1704.

Abstract

The adhesion capacities, transmigration capacities, and integrin expression of lymphocytes from patients with Guillain-Barré syndrome incubated with interferon-beta were studied. Interferon-beta induced a dose-dependent inhibition of lymphocyte adhesion to recombinant vascular adhesion molecule-1 (p < 0.0001) and recombinant intercellular adhesion molecule-1 (rICAM-1) (p < 0.01) without modulation of very late activation molecule-4 and lymphocyte function-associated antigen-1 expressions and a dose-dependent decrease of lymphocyte transmigration across fibronectin (p < 0.0001). Inhibition of adhesion to rICAM-1 was similar after long (18 hours) or short (5 minutes) incubation time. These results support the potential therapeutic benefit of interferon-beta in Guillain-Barré syndrome.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Cell Adhesion / drug effects
  • Cell Adhesion / immunology
  • Cell Movement / drug effects
  • Cell Movement / immunology
  • Dose-Response Relationship, Drug
  • Flow Cytometry
  • Guillain-Barre Syndrome / drug therapy*
  • Guillain-Barre Syndrome / immunology*
  • Humans
  • In Vitro Techniques
  • Integrin alpha4beta1
  • Integrins / analysis
  • Interferon-beta / administration & dosage*
  • Lymphocyte Function-Associated Antigen-1 / analysis
  • Lymphocytes / chemistry
  • Lymphocytes / cytology*
  • Receptors, Lymphocyte Homing / analysis
  • Vascular Cell Adhesion Molecule-1 / pharmacology

Substances

  • Adjuvants, Immunologic
  • Integrin alpha4beta1
  • Integrins
  • Lymphocyte Function-Associated Antigen-1
  • Receptors, Lymphocyte Homing
  • Vascular Cell Adhesion Molecule-1
  • Interferon-beta